Some hospital executives and cancer researchers sit on the boards of publicly traded companies, raising questions about whether their dual roles create a conflict of interest. The New York Times By KATIE THOMAS and CHARLES ORNSTEIN from NYT Health https://nyti.ms/2EVPKoK
Boards of Directors, Drugs (Pharmaceuticals)
Comments
Post a Comment